Table 1 Patient demographics (N=40)
Patients | ||
|---|---|---|
Characteristics | No. | % |
Gender | ||
Men | 40 | 100 |
Age (years) | ||
Mean (range) | 58.4 (40.7–75.1) | |
Performance status (ECOG) | ||
0 | 10 | 25 |
1 | 28 | 70 |
2 | 2 | 5 |
Disease status at enrolment | ||
Local disease recurrence | 33 | 82.5 |
Locoregional disease | 7 | 17.5 |
Distant metastases | 20 | 50 |
Lung | 12 | |
Other | 8 | |
Neoadjuvant therapy | 25 | 62.5 |
Taxane–cisplatin–5FU triplets | 18 | |
Cisplatin–5FU | 6 | |
Cisplatin–docetaxel | 1 | |
Surgery | 19 | 47.5 |
Primary tumour | 7 | |
Nodal disease | 3 | |
Primary tumour and nodal disease | 8 | |
Lung node metastases | 1 | |
Adjuvant therapy | ||
RT alone | 29 | 72.5 |
RT+CT with | 26 | 65.0 |
Cisplatin | 21 | |
Taxane–cisplatin–5FU triplets | 4 | |
Cisplatin–docetaxel | 1 | |
Postoperative RT alone | 7 | 17.5 |
Postoperative RT+CT with cisplatin | 4 | |
Recurrent/metastatic disease treatment | ||
CT | 6 | 15 |
Cisplatin–5FU | 2 | |
Carboplatin–paclitaxel | 2 | |
Cisplatin | 1 | |
Taxane–cisplatin–5FU triplets | 1 | |
RT | 3 | 7.5 |
Surgery | 11 | 27.5 |
